Clinical Trial Update: Upadacitinib As a Novel Treatment for Refractory Eyelid Dermatitis [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating upadacitinib as a potential treatment for refractory eyelid dermatitis. The study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eyelid Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: Northwestern University | Conditions: Eyelid Dermatitis | EARLY_Phase 1 | Status: NOT_YET_RECRUITING